Skip to main content
Log in

Augmenting Strategies in Clozapine-Resistant Schizophrenia

  • Correspondence
  • Published:
CNS Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Remington G, Saha A, Chong SA, et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005; 19(10): 843–72

    Article  PubMed  CAS  Google Scholar 

  2. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005; 20: 409–15

    Article  PubMed  Google Scholar 

  3. Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596–8

    Article  PubMed  Google Scholar 

  4. Fenton W, Dickerson FB, Boronow JJ, et al. Placebo-controlled trial of omega-3 fatty acid in schizophrenia. Schizophrenia Research 2001; 49 Suppl 1-2: 227

    Google Scholar 

  5. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7–18

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Remington, G., Saha, A., Chong, SA. et al. Augmenting Strategies in Clozapine-Resistant Schizophrenia. CNS Drugs 20, 171 (2006). https://doi.org/10.2165/00023210-200620020-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200620020-00008

Keywords

Navigation